Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial
Primary result · Change from baseline in HbA1cResult — go to the resultEstimated treatment difference −0.77 % 95% CI −0.98% to −0.56%Authors' conclusion
In SURPASS-SWITCH, switching treatment to tirzepatide provided additional HbA1c reduction and weight loss compared with escalating treatment with dulaglutide.
Study context
- Population
- Adults with T2D, hemoglobin A1c (HbA1c) ≥7.0% to ≤9.5%, stable body weight, BMI ≥25 kg/m², on stable dulaglutide (0.75 or 1.5 mg) ≥6 months and 0–3 oral antihyperglycemic medications ≥3 months; 38 sites, 5 countriesrandomized
- Participants
- 282 adults
- Comparison
- Switching to tirzepatide vs dulaglutide dose escalation
- Tirzepatiden = 139
- Dulaglutiden = 143reference
- Primary endpoint
- Change from baseline in HbA1c
- Follow-up
- Week 40
Methodological detailsmulticenter, open-label, phase 4, Limitation: open-label design
- Multicenter
- Open-label
- Phase 4
- Limitation: open-label design
Primary result
As reported in the abstract
Estimated treatment difference
−0.77 %
95% CI −0.98% to −0.56%
P < 0.001
Change by group
Tirzepatide
−1.44
SE 0.07 · %
Dulaglutide
−0.67
SE 0.08 · %
Tirzepatidevs Dulaglutide
estimated treatment difference −0.77 % (95% CI −0.98% to −0.56%); P < 0.001
Secondary outcomes
kg
| Outcome | Tirzepatide | Dulaglutide | Estimated treatment difference (kg) (CI) | P value | |
|---|---|---|---|---|---|
| Key secondary: change from baseline in weight · week 40 | −10.5 (SE 0.5) | −3.6 (SE 0.5) | −6.9 (−8.3 to −5.5 kg) | P < 0.001 | |
| −10−505Difference, kg (linear scale) |
Safety
Serious adverse events
Serious adverse events
- Most common treatment-emergent adverse events were nausea and diarrhea
Original publication
Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. Ann Intern Med. Published 4 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →